Last reviewed 2026-05-14 · How we verify

Grippol Quadrivalent

Grippol Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.

Grippol Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.

At a glance

Mechanism of action

The vaccine contains inactivated (killed) influenza virus particles or antigens from four different influenza strains (two A subtypes and two B lineages). Upon administration, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and T-cell immunity that protect against infection with matching circulating influenza viruses.

Approved indications

• Seasonal influenza prevention in adults and children

Common side effects

• Injection site pain or erythema
• Myalgia
• Headache
• Low-grade fever

Key clinical trials

• Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers (PHASE2, PHASE3)
• A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Grippol Quadrivalent CI brief — competitive landscape report
• Grippol Quadrivalent updates RSS · CI watch RSS
• NPO Petrovax portfolio CI